利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

41 条记录 (耗时 0.015 秒)

    Immunotoxins for treatment of intracranial lesions and as adjunct to chemotherapy
    1.
    发明授权
    Immunotoxins for treatment of intracranial lesions and as adjunct to chemotherapy 失效
    用于治疗颅内损伤和辅助化疗的免疫毒素

    公开(公告)号：US5352447A

    公开(公告)日：1994-10-04

    申请号：US925417

    申请日：1992-08-10

    申请人： Virginia Johnson ,  Richard J. Youle

    发明人： Virginia Johnson ,  Richard J. Youle

    IPC分类号： A61K38/00 ,  A61K47/48 ,  C07K14/34 ,  A61K39/44 ,  A61K37/04 ,  C07K17/02

    CPC分类号： A61K47/48592 ,  A61K47/483 ,  A61K47/48484 ,  A61K47/48623 ,  C07K14/34 ,  A61K38/00 ,  Y10S424/832

    摘要： A potent and specific immunotoxin is prepared by coupling a binding-site inactivated diphtheria toxin (CRM 107) to a new binding moiety consisting of transferrin or a monoclonal antibody against the human transferrin receptor. These immunotoxins are tumor specific and lack the nonspecific toxicity produced by the binding activity of the native toxin. The immunotoxin is useful in treating primary brain tumors, metastatic tumors to the brain, CSF-borne tumors, leptomeningeal leukemia and leptomeningeal carcinomatosis.

    摘要翻译： 通过将结合位点灭活的白喉毒素（CRM 107）与由转铁蛋白或针对人转铁蛋白受体的单克隆抗体组成的新结合部分偶联来制备有效和特异性的免疫毒素。 这些免疫毒素是肿瘤特异性的，并且缺乏由天然毒素的结合活性产生的非特异性毒性。 免疫毒素可用于治疗原发性脑肿瘤，转移性脑肿瘤，脑脊液肿瘤，脑膜性白血病和脑膜炎等。

    Anti-endotoxin, interleukin-1 receptor antagonist and anti-tumor necrosis factor antibody with arginine-free formulations for the treatment of hypotension
    2.
    发明授权
    Anti-endotoxin, interleukin-1 receptor antagonist and anti-tumor necrosis factor antibody with arginine-free formulations for the treatment of hypotension 失效
    抗内毒素，白细胞介素-1受体拮抗剂和抗肿瘤坏死因子抗体与无精氨酸制剂治疗低血压

    公开(公告)号：US5334380A

    公开(公告)日：1994-08-02

    申请号：US910868

    申请日：1992-06-30

    申请人： Robert G. Kilbourn ,  Owen W. Griffith ,  Steven S. Gross

    发明人： Robert G. Kilbourn ,  Owen W. Griffith ,  Steven S. Gross

    IPC分类号： A61K31/415 ,  A61K31/715 ,  A61K38/04 ,  A61K38/19 ,  A61K37/02 ,  A61K37/04 ,  A61K37/18

    CPC分类号： A61K31/415 ,  A61K31/715 ,  A61K38/20 ,  A61K39/395

    摘要： Methods and compositions for treating and inhibiting hypotension related to both endotoxin and cytokine-induced shock are provided. A therapeutic regimen useful in the present invention includes an arginine-free parenteral formulation administered with or followed by the administration of an anti-endotoxin antibody, an interleukin-1 or interleukin-2 receptor antagonist, an anti-tumor necrosis factor antibody or a combination thereof. Most preferably, the administration of an arginine-free parenteral formulation augments the anti-hypotensive effect of the various antibodies and antagonist described so as to provide an effective treatment for various forms of hypotension. The therapeutic regimens of the invention are proposed to provide for a decrease in nitric oxide synthase, and thereby an increase in blood pressure in vivo, particularly in animals with cytokine- and/or endotoxin-induced hypotension. The parenteral formulation of the therapeutic regimen and methods of the invention are arginine-free and provide a decrease in plasma arginine levels. Reduced plasma, serum, or tissue levels of arginine in the animal function to augment the hypertensive action of the various antibodies and antagonist to be administered concurrently or subsequent to the administration of the parenteral formulation. Limiting and/or eliminating substrate arginine for nitric oxide synthesis, coupled with limiting and/or eliminating induction of nitric oxide synthase activity with the antibodies and antagonists of the present invention, provides a regimen for treating and/or inhibiting hypotension attendant a variety of conditions and treatments, including chemotherapeutic agent therapy (IFN, TNF, IL-1, IL-2), septic shock, trauma, exposure to endotoxins or cytokines, or other conditions in which hypotension is attendant.

    摘要翻译： 提供了治疗和抑制与内毒素和细胞因子诱导的休克有关的低血压的方法和组合物。 用于本发明的治疗方案包括给予或随后施用抗内毒素抗体，白细胞介素-1或白细胞介素-2受体拮抗剂，抗肿瘤坏死因子抗体或组合的无精氨酸胃肠外制剂 其中。 最优选地，施用不含精氨酸的肠胃外制剂增加了所描述的各种抗体和拮抗剂的抗低血压作用，以便为各种形式的低血压提供有效的治疗。 本发明的治疗方案被提出用于减少一氧化氮合酶，从而提高体内血压，特别是在具有细胞因子和/或内毒素诱导的低血压的动物中。 本发明的治疗方案和方法的肠胃外制剂是无精氨酸的并且提供血浆精氨酸水平的降低。 在动物功能中降低精氨酸的血浆，血清或组织水平，以增加在肠胃外制剂的同时或之后施用的各种抗体和拮抗剂的高血压作用。 限制和/或消除用于一氧化氮合成的底物精氨酸，加上限制和/或消除与本发明的抗体和拮抗剂的一氧化氮合成酶活性的诱导，提供了治疗和/或抑制伴有多种病症的低血压的方案 和治疗方法，包括化疗药物治疗（IFN，TNF，IL-1，IL-2），脓毒性休克，创伤，暴露于内毒素或细胞因子，或其他伴有低血压的病症。

    Fibronectin solution suitable for use in humans and process for its preparation
    4.
    发明授权
    Fibronectin solution suitable for use in humans and process for its preparation 失效
    适用于人类的纤连蛋白溶液及其制备方法

    公开(公告)号：US4727059A

    公开(公告)日：1988-02-23

    申请号：US945095

    申请日：1986-11-24

    申请人： Bernd Binder ,  Peter Nemeth

    发明人： Bernd Binder ,  Peter Nemeth

    IPC分类号： A61K38/00 ,  A61L2/00 ,  C07K14/78 ,  A61K37/04 ,  A61K35/16 ,  C07K15/14

    CPC分类号： A61L2/0023 ,  C07K14/78 ,  A61K38/00

    摘要： A fibronectin injectable solution is made by recovering a fibronectin-containing raw material which is solubilized, provided with stabilizers and then subjected to an initial heat treatment at 57.degree. to 60.degree. for at least ten hours. After fibronectin concentration and the addition of further stabilizers and plasma-protein vehicle, the solution is again subjected to a temperature of 60.degree. for ten hours to provide an injectable solution which is free from virulent hepatitis.

    摘要翻译： PCT No.PCT / AT86 / 00026 Sec。 371日期：1986年11月24日 102（e）1986年11月24日PCT PCT公布1986年3月28日PCT公布。 出版物WO86 / 05690 日期：1986年10月9日。纤维连接蛋白可注射溶液通过回收溶解的含纤连蛋白的原料制成，提供稳定剂，然后在57℃至60℃下进行初始热处理至少10小时。 在纤连蛋白浓度和加入其他稳定剂和血浆蛋白载体后，再将溶液温度保持在60℃，保持10小时，得到无毒性肝炎的注射液。

    Urea-linked immunogens, antibodies, and preparative method
    9.
    发明授权
    Urea-linked immunogens, antibodies, and preparative method 失效
    尿素连接的免疫原，抗体和制备方法

    公开(公告)号：US4486344A

    公开(公告)日：1984-12-04

    申请号：US479757

    申请日：1983-03-28

    申请人： Robert T. Buckler

    发明人： Robert T. Buckler

    IPC分类号： A61K39/00 ,  G01N33/531 ,  A61K37/04

    CPC分类号： G01N33/531 ,  Y10S530/806 ,  Y10S530/809

    摘要： Immunogen conjugates comprising amino-functionalized haptens coupled through a carbonyl bridge to amino groups in immunogenic proteins and polypeptides. The resulting simple urea linkage in the conjugate is hydrophilic and contributes essentially no haptenic determinants. The immunogen is characterized by a high epitopic density. The method involves reaction of the hapten with a carbonyl diimidazole followed by addition of the protein or polypeptide carrier. Protein crosslinking problems common to prior art coupling methods are avoided.

    摘要翻译： 包含通过羰基桥连接到免疫原性蛋白质和多肽中的氨基的氨基官能化半抗原的免疫原缀合物。 所得到的缀合物中的简单脲键是亲水性的，并且基本上没有半抗原决定簇。 免疫原的特征在于高的表位密度。 该方法包括半抗原与羰基二咪唑的反应，随后加入蛋白质或多肽载体。 避免了现有技术偶联方法常见的蛋白质交联问题。